While many groups are looking for strategies aimed at directly targeting Myc (Soucek et al., 2008; Hogarty and Maris, 2012), recent discoveries opened the possibility to deliver target therapies for MNA tumors based on synthetic lethal approaches (Molenaar et al., 2009; Cole et al., 2011) or by enhancing the anti-cancer pathways intrinsically activated by MYCN. This evidence concerns the gene MYC and cancer.